Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 71

1.

Increase and decrease of measurements of iris density of glaucoma patients treated with latanoprost over 36 months.

Schwartz B, Takamoto T, Martin J.

J Ocul Pharmacol Ther. 2008 Feb;24(1):94-103. doi: 10.1089/jop.2007.0054.

PMID:
18370880
2.

A 12-month, randomized, double-masked study comparing latanoprost with timolol in pigmentary glaucoma.

Mastropasqua L, Carpineto P, Ciancaglini M, Gallenga PE.

Ophthalmology. 1999 Mar;106(3):550-5.

PMID:
10080213
3.

[Increased iris pigmentation after use of latanoprost in Japanese brown eyes].

Hara T.

Nippon Ganka Gakkai Zasshi. 2001 May;105(5):314-21. Japanese.

PMID:
11406947
4.

A 5-year, multicenter, open-label, safety study of adjunctive latanoprost therapy for glaucoma.

Alm A, Schoenfelder J, McDermott J.

Arch Ophthalmol. 2004 Jul;122(7):957-65.

PMID:
15249358
5.

A study of iridectomy histopathologic features of latanoprost- and non-latanoprost-treated patients.

Albert DM, Gangnon RE, Zimbric ML, Damico CM, Fisher MR, Gleiser J, Grossniklaus HE, Green WR.

Arch Ophthalmol. 2004 Nov;122(11):1680-5.

PMID:
15534130
6.

Incidence of iris colour change in latanoprost treated eyes.

Teus MA, Arranz-Márquez E, Lucea-Suescun P.

Br J Ophthalmol. 2002 Oct;86(10):1085-8.

7.

Iridial pigmentation induced by latanoprost ophthalmic solution in Japanese glaucoma patients.

Chiba T, Kashiwagi K, Kogure S, Abe K, Shibuya T, Furuichi M, Iijima H, Tsukahara S.

J Glaucoma. 2001 Oct;10(5):406-10.

PMID:
11711839
8.

Latanoprost: experience of 2-year treatment in Scandinavia.

Alm A, Widengård I.

Acta Ophthalmol Scand. 2000 Feb;78(1):71-6.

9.
10.

Effect of age on the development of a latanoprost-induced increase in iris pigmentation.

Arranz-Marquez E, Teus MA.

Ophthalmology. 2007 Jul;114(7):1255-8. Epub 2007 Feb 16.

PMID:
17306877
11.

Histology and fine structure of the iris and outflow system following latanoprost therapy.

Grierson I, Pfeiffer N, Cracknell KP, Appleton P.

Surv Ophthalmol. 2002 Aug;47 Suppl 1:S176-84. Review.

PMID:
12204715
12.

Analysis of irises with a latanoprost-induced change in iris color.

Arranz-Marquez E, Teus MA, Saornil MA, Mendez MC, Gil R.

Am J Ophthalmol. 2004 Oct;138(4):625-30.

PMID:
15488791
13.

Histological effects in the iris after 3 months of latanoprost therapy: the Mainz 1 study.

Pfeiffer N, Grierson I, Goldsmith H, Hochgesand D, Winkgen-Böhres A, Appleton P.

Arch Ophthalmol. 2001 Feb;119(2):191-6.

PMID:
11176979
14.

Incidence and severity of iris pigmentation on latanoprost-treated glaucoma eyes.

Chou SY, Chou CK, Kuang TM, Hsu WM.

Eye (Lond). 2005 Jul;19(7):784-7.

PMID:
15359238
15.

Measurement of iris color using computerized image analysis.

Takamoto T, Schwartz B, Cantor LB, Hoop JS, Steffens T.

Curr Eye Res. 2001 Jun;22(6):412-9.

PMID:
11584340
16.

A study of histopathological features of latanoprost-treated irides with or without darkening compared with non-latanoprost-treated irides.

Albert DM, Gangnon RE, Grossniklaus HE, Green WR, Darjatmoko S, Kulkarni AD.

Arch Ophthalmol. 2008 May;126(5):626-31. doi: 10.1001/archopht.126.5.626. Erratum in: Arch Ophthalmol. 2008 Oct;126(10):1403.

17.

A prospective study of iridial pigmentation and eyelash changes due to ophthalmic treatment with latanoprost.

Chiba T, Kashiwagi K, Ishijima K, Furuichi M, Kogure S, Abe K, Chiba N, Tsukahara S.

Jpn J Ophthalmol. 2004 Mar-Apr;48(2):141-7.

PMID:
15060793
19.

[Adverse reaction after use of latanoprost in Japanese glaucoma patients].

Inoue K, Wakakura M, Inoue J, Matsuo H, Hara T, Tomita G.

Nippon Ganka Gakkai Zasshi. 2006 Aug;110(8):581-7. Japanese.

PMID:
16972649
20.

The additive effect of latanoprost to maximum-tolerated medications with low-dose, high-dose, or no pilocarpine therapy.

Shin DH, McCracken MS, Bendel RE, Pearlman R, Juzych MS, Hughes BA, Schulz LL, Kim C, Baek NH.

Ophthalmology. 1999 Feb;106(2):386-90.

PMID:
9951495

Supplemental Content

Support Center